ALNY Alnylam Pharmaceuticals

Q2 2025 10-Q

Filed: Jul 31, 2025Period ending Jun 30, 2025

Health Care

Pharmaceutical PreparationsSEC EDGAR

Alnylam Pharmaceuticals (ALNY) 10-Q quarterly report for Q2 2025, filed with SEC EDGAR on Jul 31, 2025 for the fiscal period ending Jun 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q2 2025 10-Q

Management Discussion & Analysis

• Cash, cash equivalents, marketable securities sufficient for next 12 months from filing date
• Potential need for significant additional funds earlier than expected

+1 more insights

Quarterly Financial Summary
XBRL

Revenue

$774M

Net Income

-$66M

Net Margin

-8.6%

Source: XBRL data from Alnylam Pharmaceuticals Q2 2025 10-Q filing on SEC EDGAR. All figures in USD.

Other Alnylam Pharmaceuticals Quarterly Reports

Q3 2025 10-Q

Get deeper insights on Alnylam Pharmaceuticals

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.